Excimer laser alternative for psoriasis:
This article was originally published in Clinica
Executive Summary
Laser Photonics subsidiary Acculase has applied for 510(k) marketing clearance in the US for its excimer laser to treat skin diseases such as psoriasis. It claims that the laser method will result in shorter treatment courses with fewer sessions than the currently used ultra-violet phototherapy, while avoiding exposure of the patient's whole body to ultraviolet light. Psoriasis affects 2% of the world's population and treatment costs are $5 billion in the US alone, said Carlsbad, California-based Laser Photonics.
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.